Skip to content

CEVENFACTA® Indication

CEVENFACTA® is indicated in adults and adolescents (12 years of age and older) for the treatment of bleeding episodes and for the prevention of bleeding in those undergoing surgery or invasive procedures in the following patient groups:

  • in patients with congenital haemophilia with high-responding inhibitors to coagulation factors VIII or IX (i.e. ≥5 Bethesda Units (BU));
  • in patients with congenital haemophilia with low titre inhibitors (BU <5), but expected to have a high anamnestic response to factor VIII or factor IX administration or expected to be refractory to increased dosing of FVIII or FIX

CEVENFACTA® should be prescribed by physicians experienced in the treatment of haemophilia and/or bleeding disorders.

Prescribing Information for CEVENFACTA® can be found 

ADVERSE EVENTS
Adverse events should be reported. Reporting forms and information can be found at .
Adverse events should also be reported to Medical Information, Pharmalex, Tel: 01628 531171 medinfo.uk@pharmalex.com

PRESCRIBING INFORMATION

PATIENT WEBSITE

COOKIES MANAGEMENT PANEL

23/05/019 | August 2023 | Copyright © 2025 LFB

Scroll to Top